Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 4
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
ALK fusion
gastric cancer · Therapy Not Normalized
ALK fusion is flagged as trial selection rising because public trials show inclusion required evidence in 4 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 3
Common snippets: dMMR | dMMR | dMMR
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT01657214 | https://clinicaltrials.gov/study/NCT02037048 | https://clinicaltrials.gov/study/NCT06059495 | https://clinicaltrials.gov/study/NCT07103668